Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROBENECID W/ COLCHICINE vs ANTURANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Probenecid inhibits renal tubular reabsorption of uric acid, increasing its excretion. Colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory cell chemotaxis.
Uricosuric agent; inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.
Prophylaxis and treatment of acute gout flares,Hyperuricemia associated with gout (probenecid component)
Treatment of chronic gout,Prophylaxis of acute gouty attacks during initiation of allopurinol or uricosuric therapy,Off-label: Prevention of calcium oxalate calculi in hyperuricosuric patients
1 tablet (500 mg probenecid / 0.5 mg colchicine) orally twice daily, with or without food.
200-400 mg orally twice daily
Probenecid: 5-8 hours (terminal half-life, prolonged in renal impairment); Colchicine: 26-31 hours (mean terminal half-life in adults, can be extended in elderly or renal/hepatic impairment).
Terminal elimination half-life is approximately 4–6 hours for the parent drug; active sulfide metabolite has a half-life of 12–16 hours. Clinically, twice-daily dosing maintains therapeutic levels.
Probenecid: Hepatic via glucuronidation, oxidation; inhibits renal tubular secretion of many drugs. Colchicine: Hepatic via CYP3A4 and P-glycoprotein (P-gp); undergoes enterohepatic recirculation.
Primarily hepatic oxidation and glucuronidation; minor CYP450 involvement.
Probenecid: Renal (70-80% as unchanged drug and metabolites, primarily via tubular secretion); Colchicine: Hepatic metabolism (approx. 80%) and renal excretion (10-20% unchanged). Fecal excretion of metabolites accounts for a minor fraction.
Renal excretion: approximately 50% of the dose as unchanged drug and its active sulfide metabolite via glomerular filtration and tubular secretion; biliary/fecal: ~30%, primarily as metabolites.
Probenecid: 85-95% bound to plasma albumin; Colchicine: 39-44% bound to albumin and alpha1-acid glycoprotein.
99% bound, primarily to albumin.
Probenecid: 0.15-0.2 L/kg (highly confined to plasma and extracellular fluid); Colchicine: 2-5 L/kg (extensive tissue distribution, particularly in leukocytes and liver).
0.15–0.3 L/kg, indicating limited extravascular distribution; primarily remains in plasma and extracellular fluid.
Probenecid: Oral bioavailability approximately 100% (well absorbed, but first-pass metabolism reduces systemic exposure to parent drug); Colchicine: Oral bioavailability 24-45% (subject to first-pass metabolism and transport by P-glycoprotein).
Oral: Approximately 90% absorbed, but extensive first-pass metabolism reduces systemic bioavailability of parent drug to 30–40%; active sulfide metabolite contributes to efficacy.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min, reduce dose to 1 tablet once daily; for GFR > 50 m L/min, no adjustment needed.
Contraindicated if Cr Cl <30 m L/min. For Cr Cl 30-50 m L/min, reduce dose by 50%. For Cr Cl >50 m L/min, no adjustment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce colchicine dose by 50% (use combination product cautiously); Child-Pugh C: contraindicated due to colchicine toxicity risk.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Not recommended for pediatric use; safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start with 1 tablet once daily; monitor renal function and colchicine toxicity due to age-related decline in GFR and increased sensitivity.
Start at low end of dosing range (200 mg twice daily); monitor renal function. Caution due to increased sensitivity and renal impairment.
Colchicine can cause fatal toxicity if not dosed correctly; fatalities have occurred with doses as low as 0.8 mg in patients with renal or hepatic impairment, or in combination with P-glycoprotein or CYP3A4 inhibitors.
None.
Blood dyscrasias (aplastic anemia, agranulocytosis), hepatotoxicity, neuromuscular toxicity, renal impairment, drug interactions with P-gp and CYP3A4 inhibitors, use with caution in elderly and debilitated patients.
Acute gouty attacks may occur during initiation; prophylactic colchicine or NSAIDs recommended,Monitor renal function; dose adjustment in renal impairment,Avoid in patients with high urinary uric acid output to prevent uric acid stones,May potentiate warfarin; monitor INR,Cross-allergenicity with sulfonamides possible
Hypersensitivity to probenecid or colchicine, concurrent use of P-gp or strong CYP3A4 inhibitors (e.g., clarithromycin, cyclosporine, ketoconazole), severe renal impairment (Cr Cl <30 m L/min), severe hepatic impairment, pre-existing blood dyscrasias.
Severe renal impairment (Cr Cl <50 m L/min),History of hypersensitivity to sulfinpyrazone or sulfonamides,Active peptic ulcer disease,Blood dyscrasias,Uric acid nephropathy or stone formation
Avoid high-purine foods (organ meats, shellfish, red meat, beer) as they increase uric acid and reduce drug efficacy. Alcohol, especially beer, contraindicated. Acidic foods (cranberries, citrus) may increase colchicine absorption; limit large amounts. Grapefruit may increase colchicine levels; avoid.
Avoid alcohol as it increases uric acid levels and may decrease drug efficacy. Maintain adequate hydration; avoid excessive intake of high-purine foods (e.g., organ meats, sardines, anchovies) to help control gout.
Risk cannot be ruled out. Colchicine is associated with chromosomal abnormalities and fetal harm at high doses in animal studies; human data limited. Probenecid not teratogenic in animals. First trimester: avoid unless benefit outweighs risk. Second/third trimester: use only if clearly needed.
Anturane (sulfinpyrazone) is a uricosuric agent. There are no adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at doses up to 10 times the human dose. However, due to its potential to inhibit platelet aggregation, use during pregnancy, especially near term, may increase the risk of maternal and fetal hemorrhage. First trimester: No specific fetal risks identified, but caution advised. Second trimester: Risks unclear; avoid unless necessary. Third trimester: Potential for premature closure of ductus arteriosus (unlikely as it is not an NSAID) and bleeding risk; avoid near term.
Colchicine: limited excretion into breast milk; M/P ratio ~0.4; low relative infant dose (~5% maternal weight-adjusted dose). Probenecid: excreted in milk but no adverse reports. Consider alternative if infant <3 months or G6PD deficiency.
Sulfinpyrazone is excreted into human milk in small amounts. The milk-to-plasma (M/P) ratio is not well established but is likely low (<0.2). Due to potential adverse effects in the nursing infant (e.g., bleeding risk, interference with platelet function), caution is recommended. The benefits of breastfeeding should be weighed against the potential risks, and alternative therapies considered.
No specific dose adjustments required; however, increased glomerular filtration rate in pregnancy may reduce probenecid efficacy; colchicine clearance unchanged. Monitor clinical response and titrate dose if needed.
Pregnancy can alter pharmacokinetics of drugs due to increased plasma volume, renal blood flow, and hepatic metabolism. For sulfinpyrazone, no specific dose adjustment guidelines are established for pregnancy. Given its uricosuric action, the increased glomerular filtration rate during pregnancy may enhance clearance, potentially requiring higher doses to maintain therapeutic effect. However, due to potential risks, use should be avoided if possible. If used, monitor serum uric acid levels and adjust dose accordingly, starting with the lowest effective dose.
Probenecid reduces renal excretion of colchicine, increasing colchicine toxicity risk; dose adjustment required. Contraindicated in G6PD deficiency and blood dyscrasias. Monitor CBC and renal function. Use with caution in patients with peptic ulcer disease (probenecid may exacerbate). Colchicine neuromyopathy risk increases with concurrent statins or cyclosporine.
Anturane (sulfinpyrazone) is a uricosuric agent used for chronic gout. It is contraindicated in patients with peptic ulcer disease due to GI irritation. Monitor renal function and uric acid levels. Avoid use in patients with a history of uric acid stones; maintain high fluid intake to prevent stone formation. Not effective in acute gout attacks. Discontinue at least 48 hours before surgery to avoid bleeding risk due to antiplatelet effects.
Take with food or milk to reduce GI upset.,Drink plenty of fluids (2-3 L/day) to prevent kidney stones and help urate excretion.,Avoid alcohol, as it can increase uric acid levels and precipitate gout attacks.,Stop at first signs of infection, sore throat, or easy bruising (myelosuppression).,Report muscle pain or weakness (colchicine myopathy), especially if on statins.,Do not exceed prescribed dose; colchicine overdose can be fatal.,May cause gout flares initially; continue medication and contact provider if flares persist.
Take with food or milk to reduce stomach upset.,Drink at least 8 glasses of water daily to prevent kidney stones.,Avoid aspirin and other salicylates as they reduce drug effectiveness.,Report any signs of bleeding (bruising, black stools) or stomach pain.,Do not stop suddenly without consulting your doctor.,This drug is not for acute gout attacks; continue other medications as prescribed.
"Colchicine may decrease the cardiotoxic effects of Deslanoside by reducing its absorption or altering its pharmacokinetics, potentially leading to subtherapeutic digoxin levels and reduced efficacy. This interaction could increase the risk of atrial fibrillation or heart failure exacerbation in patients requiring cardiac glycoside therapy. Clinical outcomes may include loss of rate control in atrial fibrillation or decreased inotropic support in heart failure."
"Colchicine, a substrate of CYP3A4 and P-glycoprotein (P-gp), can inhibit CYP2D6 and to a lesser extent CYP3A4 at therapeutic concentrations. Fluvoxamine, a potent CYP1A2 and moderate CYP2C9/3A4 inhibitor, may have its serum concentration increased by colchicine via competition for CYP3A4 and P-gp efflux, although colchicine's inhibition of CYP3A4 is weak. This interaction could potentiate fluvoxamine's serotonergic adverse effects, including serotonin syndrome, as well as increase the risk of QT prolongation and sedation. However, clinical significance is generally low unless high doses of colchicine are used."
"Colchicine and sildenafil both utilize cytochrome P450 3A4 (CYP3A4) for metabolism. Concurrent administration can lead to competitive inhibition of CYP3A4, resulting in increased plasma concentrations of sildenafil. Elevated sildenafil levels may potentiate its vasodilatory effects, increasing the risk of hypotension, priapism, and other adverse events."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROBENECID W/ COLCHICINE vs ANTURANE, answered by our medical review team.
PROBENECID W/ COLCHICINE is a Uricosuric that works by Probenecid inhibits renal tubular reabsorption of uric acid, increasing its excretion. Colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory cell chemotaxis.. ANTURANE is a Uricosuric that works by Uricosuric agent; inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROBENECID W/ COLCHICINE and ANTURANE depend on the specific clinical indication. These are both Uricosuric agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROBENECID W/ COLCHICINE is: 1 tablet (500 mg probenecid / 0.5 mg colchicine) orally twice daily, with or without food.. The standard adult dose of ANTURANE is: 200-400 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROBENECID W/ COLCHICINE and ANTURANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROBENECID W/ COLCHICINE is classified as Category A/B. Risk cannot be ruled out. Colchicine is associated with chromosomal abnormalities and fetal harm at high doses in animal studies; human data limited. Probenecid not teratogenic in . ANTURANE is classified as Category C. Anturane (sulfinpyrazone) is a uricosuric agent. There are no adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.